Innate Pharma, Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.3M
Doctors Paid
135
Transactions
299
2021 Total
$172,701
Payment Breakdown by Category
Research$3.3M (97.8%)
Consulting$29,136 (0.9%)
Food & Beverage$3,464 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 170 | 97.8% |
| Honoraria | $39,750 | 20 | 1.2% |
| Consulting Fee | $29,136 | 9 | 0.9% |
| Food and Beverage | $3,464 | 100 | 0.1% |
Payments by Type
Research
$3.3M
170 transactions
General
$72,350
129 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | $2.2M | 0 | 88 |
| An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma | $440,121 | 1 | 24 |
| A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti) and Rituximab (Rituxan) for Relapsed Hairy Cell Leukemia | $212,080 | 0 | 2 |
| A Phase I Study of the Anti-C5aR, Avdoralimab (IPH5401), in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors | $155,954 | 0 | 23 |
| A phase-I study of the anti-C5aR, IPH5401, in combination with the anti-PDL-1, durvalumab, in patients with selected advanced solid tumors | $150,989 | 6 | 20 |
| Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | $129,531 | 0 | 13 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Medical Oncology | $140,001 | 19 | $7,368 |
| Hematology & Oncology | $40,770 | 72 | $566.25 |
| Internal Medicine | $21,440 | 18 | $1,191 |
| Dermatopathology | $14,848 | 1 | $14,848 |
| Hematology | $11,868 | 13 | $912.91 |
| Specialist | $1,268 | 6 | $211.30 |
| Dermatology | $483.33 | 1 | $483.33 |
| Hospice and Palliative Medicine | $36.91 | 2 | $18.46 |
| Gynecologic Oncology | $19.03 | 1 | $19.03 |
| Pediatrics | $12.35 | 1 | $12.35 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Thomas Marron, M.d. Ph.d, M.D. PH.D | Medical Oncology | New York, NY | $41,453 | $0 |
| Dr. Anthony Tolcher | Medical Oncology | San Antonio, TX | $38,453 | $0 |
| David Hsieh, M.d, M.D | Medical Oncology | Dallas, TX | $38,118 | $0 |
| Vivek Sharma, Md, MD | Hematology & Oncology | Louisville, KY | $14,965 | $0 |
| Dr. Alejandro Gru, Md, MD | Dermatopathology | New York, NY | $14,848 | $0 |
| Dylan Zylla, Md, MD | Internal Medicine | Saint Louis Park, MN | $10,500 | $0 |
| Mario Sznol, Md, MD | Medical Oncology | North Miami, FL | $7,920 | $0 |
| Johanna Bendell, M.d, M.D | Medical Oncology | Nashville, TN | $7,500 | $0 |
| Dr. James Blachly, M.d, M.D | Hematology | Columbus, OH | $4,200 | $0 |
| Dr. Tanguy Seiwert, M.d, M.D | Medical Oncology | Baltimore, MD | $3,960 | $0 |
| Pierluigi Porcu, M.d, M.D | Hematology & Oncology | Philadelphia, PA | $3,900 | $0 |
| Farhad Ravandi-Kashani, M.d, M.D | Hematology & Oncology | Houston, TX | $3,500 | $0 |
| Dr. Kerry Rogers, Md, MD | Hematology | Columbus, OH | $3,300 | $0 |
| Deborah Stephens, D.o, D.O | Hematology & Oncology | Salt Lake City, UT | $3,300 | $0 |
| Parameswaren Venugopal, M.d, M.D | Hematology | Chicago, IL | $2,400 | $0 |
| Stephen Spurgeon, Md, MD | Internal Medicine | Portland, OR | $2,400 | $0 |
| Charles Schiffer, Md, MD | Internal Medicine | Detroit, MI | $2,400 | $0 |
| Dr. Tanya Siddiqi, M.d, M.D | Internal Medicine | Duarte, CA | $2,400 | $0 |
| William Robinson, Md, MD | Medical Oncology | Aurora, CO | $2,400 | $0 |
| Dr. Mazyar Shadman, Md,Mph, MD,MPH | Hematology & Oncology | Seattle, WA | $2,400 | $0 |
| Gary Schiller, Md, MD | Hematology & Oncology | Los Angeles, CA | $2,400 | $0 |
| Robert Bociek, Md, MD | Hematology & Oncology | Omaha, NE | $2,400 | $0 |
| Leslie Andritsos, Md, MD | Hematology | Albuquerque, NM | $1,813 | $0 |
| Javier Pinilla-Ibarz, Md, MD | Internal Medicine | Tampa, FL | $1,800 | $0 |
| Dr. John Winters, Md, MD | Hematology & Oncology | Westbrook, ME | $1,200 | $0 |
About Innate Pharma, Inc
Innate Pharma, Inc has made $3.3M in payments to 135 healthcare providers, recorded across 299 transactions in the CMS Open Payments database. In 2021, the company paid $172,701. The top product by payment volume is Lumoxiti ($435,419).
Payments were distributed across 10 medical specialties. The top specialty by payment amount is Medical Oncology ($140,001 to 19 doctors).
Payment categories include: Food & Beverage ($3,464), Consulting ($29,136), Research ($3.3M).
Innate Pharma, Inc is associated with 1 products in the CMS Open Payments database.